Oisin Biotechnologies

Oisin is a decade old and still entirely preclinical, having raised only about $27.5M total — a punishingly thin balance sheet for a gene-therapy company facing the capital-intensive gauntlet of IND-enabling tox, manufacturing, and clinical trials, which means the road ahead demands far more money than Oisin has ever commanded and near-certain heavy dilution or dependence on partners. The senescence thesis itself has cooled: Unity Biotechnology, the field's best-funded senolytics pioneer, suffered high-profile clinical failures that chastened investor enthusiasm for senescent-cell clearance and raised doubts about whether clearing these cells delivers the healthspan benefits mouse models promised. Non-viral gene delivery is unforgiving — achieving efficient, safe, targeted biodistribution to senescent cells throughout the body without off-target toxicity is exactly the problem that has stymied the field, and Oisin's Fusogenix advantages remain preclinical assertions. The AbbVie Ventures round, while validating, was a modest first close of a small Series A, not a conviction-scale commitment, and pharma venture arms routinely take options they let lapse. Spreading a tiny team (1-10 employees) across senescence, muscle, and fat programs plus an OncoSenX cancer spinout risks doing none well. The company has repeatedly forecast INDs and clinical entry that keep slipping. A scientifically elegant platform starved of the capital and clinical validation to prove it, Oisin could remain a perpetual preclinical promise or become an acqui-hire for its delivery technology rather than a therapeutics winner.